Emily Mitchell, FRCPath | PhD Student

Mitchell, Emily

Emily Mitchell's research aims to investigate factors contributing to blood stem cell ageing, primarily focusing on changes at the stem cell population level.  She is a Haematology Registrar at Addenbrooke's Hospital and is also interested in understanding how ageing of the blood system contributes to the development of blood cancers. 

"I am using novel approaches based on whole genome sequencing of individual blood stem cell colonies to reconstruct changes in the blood stem cell population size over an individual's lifetime.  It is extremely exciting to be able to explore how changes at the stem cell population level could contribute to ageing and cancer development, a previously totally unexplored area."

Publications

  • Clonal approaches to understanding the impact of mutations on hematologic disease development.

    Nangalia J, Mitchell E and Green AR

    Blood 2019;133;13;1436-1445

  • GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.

    Carpenter E, Valverde-Garduno V, Sternberg A, Mitchell C, Roberts I et al.

    British journal of haematology 2005;128;4;548-51

  • GATA1 mutation analysis demonstrates two distinct primary leukemias in a child with down syndrome; implications for leukemogenesis.

    Hellebostad M, Carpenter E, Hasle H, Mitchell C and Vyas P

    Journal of pediatric hematology/oncology 2005;27;7;408-9

  • Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia.

    Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2002;13 Suppl 1;40-3

  • Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma.

    Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19;9;2472-81

  • Clonal approaches to understanding the impact of mutations on hematologic disease development.

    Nangalia J, Mitchell E and Green AR

    Blood 2019;133;13;1436-1445

  • GATA1 mutation analysis demonstrates two distinct primary leukemias in a child with down syndrome; implications for leukemogenesis.

    Hellebostad M, Carpenter E, Hasle H, Mitchell C and Vyas P

    Journal of pediatric hematology/oncology 2005;27;7;408-9

  • GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.

    Carpenter E, Valverde-Garduno V, Sternberg A, Mitchell C, Roberts I et al.

    British journal of haematology 2005;128;4;548-51

  • Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia.

    Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2002;13 Suppl 1;40-3

  • Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma.

    Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19;9;2472-81

Mitchell, Emily
Emily's Timeline
2017

Wellcome PhD for Clinicians

2016

FRCPath: Fellow of the Royal College of Pathologists

2011

Academic Clinical Fellow in Haematology, Cambridge University

2009

Core Medical Trainee, North Bristol Foundation Trust and Gloucestershire Hospitals NHS Foundation Trust

2007

Foundation Doctor, Gloucestershire Hospitals NHS Foundation Trust

BMBCh Bachelor of Medicine and Surgery, Oxford University

2003

BA Biological Sciences, Oxford University